Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Item
http://www.wikidata.org/entity/Q28200554
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?A computational model for the analysis of lipoprotein distributions in the mouse: translating FPLC profiles to lipoprotein metabolismNew peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Low Plasma Hdl Cholesterol and Elevated C Reactive Protein further Increase Cardiovascular Disease Risk in Latinos with Type 2 DiabetesNiacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS).The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humansImpact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARα-regulated β-oxidative enzymes.Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal womenEfficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review."If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.Exploration and analysis of drug modes of action through feature integration.Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome.PPAR Agonists and Metabolic Syndrome: An Established Role?
P2860

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Item
http://www.wikidata.org/entity/Q28200554
description
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im September 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 26 September 2006)
@en
vedecký článok (publikovaný 2006/09/26)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/09/26)
@nl
наукова стаття, опублікована у вересні 2006
@uk
مقالة علمية (نشرت في 26-9-2006)
@ar
name
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@ast
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@en
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@nl
type
label
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@ast
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@en
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@nl
prefLabel
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@ast
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@en
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@nl
P1433
P1476
P2093
P275
P2860
P2888
P304
P31
P356
P407
P433
P478
P5008
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Atherogenic dyslipidemia in me ...... apeutic options beyond statins
@en
P2093
P275
P2860
P2888
P304
P31
P356
P407
P433
P478
P5008
P577
P5875
P6179
P698
P921
P932